INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS
The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/...
Saved in:
| Main Authors | , , , |
|---|---|
| Format | Patent |
| Language | English |
| Published |
23.06.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments. |
|---|---|
| AbstractList | The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments. |
| Author | West, Cameron E Moore, Robert Preston West, Jason H Zaid, Gene H |
| Author_xml | – fullname: Moore, Robert Preston – fullname: West, Jason H – fullname: Zaid, Gene H – fullname: West, Cameron E |
| BookMark | eNrjYmDJy89L5WSw9_Tz8HTyDPH091Pwd1Nw9g_zdNE1tFQI8wwKDVZwilTwDfUJ8QzwcdV19vcN8Pdz9QtRcPMPAoo6gvQE8zCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-NBgIwMjI0NLYwMDc0dDY-JUAQBSzi09 |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | US2022193007A1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_US2022193007A13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Aug 16 05:52:58 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_US2022193007A13 |
| Notes | Application Number: US202117559445 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220623&DB=EPODOC&CC=US&NR=2022193007A1 |
| ParticipantIDs | epo_espacenet_US2022193007A1 |
| PublicationCentury | 2000 |
| PublicationDate | 20220623 |
| PublicationDateYYYYMMDD | 2022-06-23 |
| PublicationDate_xml | – month: 06 year: 2022 text: 20220623 day: 23 |
| PublicationDecade | 2020 |
| PublicationYear | 2022 |
| RelatedCompanies | Ankh Life Sciences Limited |
| RelatedCompanies_xml | – name: Ankh Life Sciences Limited |
| Score | 3.4126058 |
| Snippet | The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220623&DB=EPODOC&locale=&CC=US&NR=2022193007A1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhT1Dedih9TAkrfglubdvZhDJu2rLJ-sLVjPo1lZiBIN1zFv-8lTt3T3pIcHJfAfeY-AO6VXLTRjqVtYUvKbDmjjyYTVLak7aLzNlvocT5x4vQL9jyxJzV4_62F0X1Cv3RzROSoOfJ7peX16j-I5evcyvWDeMOjZS_Mu76x8Y5Ns4Xq3PC9bpClfsoNzrvFyEiGGoa2CmrEJ_SV9pQhrTrtB2NP1aWstpVKeAz7GeIrqxOoybIBh_x39loDDuLNlzcuN9y3PoVelPQjL1JBJZKGhKfjyKdtl4yjYTEi3guJi0EeZYOA8jTO0iRIcoJOHp7-FAufwV0Y5LxPkZLp38WnxWibbOsc6uWylBdALGkyR3SExZwFc-dMdCRaevarI12xmFuzS2juwnS1G3wNR2qrEqJMqwn16uNT3qDqrcStfrFvxy-BKg |
| link.rule.ids | 230,309,786,891,25594,76904 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQGlb8WtTTv7MIb9otF-sbVjPo1lZiBIN1zFf99r3HRPews5OC6Bu9_9ktwF4L6KiwbmsWqHG0KlhpiqjxrlqmgLw0LyNp3L73yi2Axy-jw2xjX42NTCyD6h37I5InrUDP29lPF6-X-I5cq3lasH_o5Ti76f9VxlzY41rY1wrrh2z0sTN3EUx-nlQyUeSBnmKoiIT8iV9rpICqtO-97IrupSltug4h_Bfor6ivIYaqJoQsPZ_L3WhINofeWNw7X3rU6gz-KA2aw6VCKJT5xkxFy1Y5ERG-RDYr-SKA8zloae6iRRmsRenBEkeTj7Wyx8Cne-lzmBipZM_hY-yYfbZutnUC8WhTgHoguNmrzLdWrOqTWjvCsw0zPeTGHx-UyfXkBrl6bL3eJbaARZFE5CFr9cwWElqh5HaXoL6uXnl7hGGC75jdy9H_eWhBU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=INHIBITION+OF+COVID-19+VIRUS+BY+MULTIPLE-COMPONENT+FORMULATIONS&rft.inventor=Moore%2C+Robert+Preston&rft.inventor=West%2C+Jason+H&rft.inventor=Zaid%2C+Gene+H&rft.inventor=West%2C+Cameron+E&rft.date=2022-06-23&rft.externalDBID=A1&rft.externalDocID=US2022193007A1 |